This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US

Hurry! $500 Savings Ends In:

  • 00
  • 00
  • 00
  • 00
December 4 - 8, 2022
Marriott Marquis San DiegoDelivered as a Hybrid Event

Sophia Karagiannis, PhD
Professor of Translational Cancer Immunology at King's College London School of Medicine


Professor Sophia Karagiannis is a translational cancer immunologist with academic and biotechnology experience in the USA and UK. She heads a cancer antibody discovery team at King’s College London focused on the crosstalk between patient immunity and cancer and on the design of novel therapeutic agents. Key areas of research centre on patient-derived B cells and antibodies, Fc-engineered antibodies of different isotypes and antibody-drug conjugates for cancer therapy. Her group is the first to design, evaluate and translate anti-tumour IgE class antibodies from concept to clinical testing. Sophia is founder of Epsilogen Ltd, the first immuno-oncology company dedicated to developing IgE-based anti-cancer agents.

Agenda Sessions

  • IgE Class Antibody Immunotherapy for Solid Tumors